ERBB2 and breast cancer: Since KCZ+BZA combination treatment targets breast cancer cells, spares normal cells, and reduces migration, these data further support the clinical utility of dual-targeting both tGLI1 and GP130 for HER2-enriched breast cancer and TNBC.